Zobrazeno 1 - 10
of 193
pro vyhledávání: '"maic"'
Autor:
Takeshi Nakahara, Hiroyuki Murota, Miyuki Matsukawa, Hiroe Takeda, Yilong Zhang, Tomohiro Kondo
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 10, Pp 2905-2916 (2024)
Abstract Background Atopic dermatitis (AD) is a chronic condition with an increasing incidence in Japan. Difamilast and delgocitinib are both new topical drugs for AD proven to be efficacious and safe in phases 2 and 3 clinical trials in Japan. Howev
Externí odkaz:
https://doaj.org/article/1bd9952dbcbb4c4ea297268b5d5b1a3b
Publikováno v:
International Journal of General Medicine, Vol Volume 17, Pp 3927-3932 (2024)
Katharine Batt,1,* Robert Klamroth,2,* Maria Elisa Mancuso,3,4,* Andreas Tiede,5,* Lorenzo G Mantovani6,7,* 1Department of Internal Medicine, Section of Hematology/Medical Oncology, Wake Forest University Baptist Medical Center, W
Externí odkaz:
https://doaj.org/article/40b046624be0472396eaed2d47567b29
Autor:
Philip J. Mease, Richard B. Warren, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Vanessa Taieb, Jason Eells, Iain B. McInnes
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 5, Pp 1413-1423 (2024)
Abstract Introduction A matching-adjusted indirect comparison (MAIC) was conducted to assess the relative efficacy at 52 weeks (Wk52) of bimekizumab 160 mg every 4 weeks (Q4W) and ustekinumab 45 or 90 mg every 12 weeks (Q12W) in patients with psoriat
Externí odkaz:
https://doaj.org/article/4262254099cb40d39645fcfe05396997
Autor:
Philip J. Mease, Richard B. Warren, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, Iain B. McInnes
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 5, Pp 1403-1412 (2024)
Abstract Introduction The relative efficacy of bimekizumab and risankizumab in patients with PsA who were biologic disease-modifying anti-rheumatic drug naïve (bDMARD naïve) or with previous inadequate response or intolerance to tumor necrosis fact
Externí odkaz:
https://doaj.org/article/ce35de981e1147979941d6203e2e5191
Autor:
David Cherney, Kerstin Folkerts, Paul Mernagh, Mateusz Nikodem, Joerg Pawlitschko, Peter Rossing, Neil Hawkins
Publikováno v:
Journal of Market Access & Health Policy, Vol 12, Iss 3, Pp 169-180 (2024)
This study aimed to close an evidence gap concerning the relative efficacy of finerenone versus SGLT2is in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). Canagliflozin was selected as a proxy for the SGLT2i class. Patient-level
Externí odkaz:
https://doaj.org/article/dff937541dc9404db1fe3b6590a96398
Publikováno v:
Frontiers in Psychology, Vol 15 (2024)
ObjectivesWith the rapid growth of China’s sprint program’s international competitiveness, the psychological problems of sprinters have become a common concern in sports training theory and practice. Hence, the study examined the impact of a 7-we
Externí odkaz:
https://doaj.org/article/e50b0f4a379b4fd2837112e041378e96
Autor:
Bérengère Macabeo, Arthur Quenéchdu, Samuel Aballéa, Clément François, Laurent Boyer, Philippe Laramée
Publikováno v:
Journal of Market Access & Health Policy, Vol 12, Iss 2, Pp 58-80 (2024)
Introduction: Health technology assessment (HTA) agencies express a clear preference for randomized controlled trials when assessing the comparative efficacy of two or more treatments. However, an indirect treatment comparison (ITC) is often necessar
Externí odkaz:
https://doaj.org/article/7ca5097be5844627ad4e12b2769b214e
Autor:
Shahrul Mt-Isa, Justin R. Chumbley, Emma L. Crawford, Natalie Banniettis, Ulrike K. Buchwald, Jessica Weaver, Thomas Weiss
Publikováno v:
Expert Review of Vaccines, Vol 22, Iss 1, Pp 906-917 (2023)
Objectives Immunogenicity between 15-valent V114 (PCV15) and 20-valent PCV20 pneumococcal conjugate vaccines in healthy infants is compared in an indirect treatment comparison and matching-adjusted indirect comparison. Hypotheses: immunogenicity of V
Externí odkaz:
https://doaj.org/article/fc924601a56e4328a69175c2ebf6d424
Autor:
Pedro Sánchez, Cecilio Álamo, Marcos Almendros, Max Schlueter, Anastasios Tasoulas, Javier Martínez
Publikováno v:
Annals of General Psychiatry, Vol 22, Iss 1, Pp 1-10 (2023)
Abstract Background Risperidone ISM® is a newly developed long-acting injectable (LAI) treatment for schizophrenia in adults. In the absence of head-to-head comparisons with other similar antipsychotics, the objective of this study was to generate i
Externí odkaz:
https://doaj.org/article/3e5a0c5edce148caad01c573e9207e1c
Autor:
April W. Armstrong, Sang Hee Park, Vardhaman Patel, Malcolm Hogan, Wei-Jhih Wang, David Davidson, Viktor Chirikov
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 11, Pp 2589-2603 (2023)
Abstract Introduction Deucravacitinib, an oral tyrosine kinase 2 (TYK2) inhibitor, is approved in the United States to treat adults with moderate-to-severe plaque psoriasis (PsO). This study compared the long-term efficacy of deucravacitinib and adal
Externí odkaz:
https://doaj.org/article/3acdd55e51df464cb2bdfcb1bfd0b3fc